Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead to Raise $36M in Private Stock Offering

Premium

Arrowhead Research this week announced that it intends to raise $36 million through a private offering of roughly 14.3 million shares plus 9,900 shares of convertible preferred stock.

The common stock will be priced at $1.83 apiece, and the preferred shares are priced at $1,000 each and are convertible into shares of common stock at a price of $1.83 per share.

Arrowhead said that the offering is expected to close by May 3.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.